IMMUNE CHECKPOINT INHIBITORS AS THE SECOND-LINE TREATMENT FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A COST-EFFECTIVENESS ANALYSIS BASED ON NETWORK META-ANALYSIS
Account has been disabled due to a violation of Terms of Service. Contact Moderators
Account has been disabled due to a violation of Terms of Service. Contact Moderators